Persephone Biosciences
Latest round
- Seed
Last raised
- Jul 2022
Total raised
- $15M
Investors
- 8
About Persephone Biosciences
a. Persephone operates as a developer of microbiome-based medicines for immuno-oncology applications. In July 2022, Persephone Biosciences, Inc. The company is developing a platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. Persephone uses synthetic biology for the development of microbial products, impacting patient and infant health. In addition, the firm has conducted multiple clinical research programs, including My Baby Biome, ARGONAUT, and Poop for the Cure.
Who invested in Persephone Biosciences
8 investors across 1 round
See all investors in Persephone Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 13, 2022
Amount
$15M
Investors
Questions about Persephone Biosciences
Who invested in Persephone Biosciences?
Persephone Biosciences has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Persephone Biosciences raised?
Persephone Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Persephone Biosciences last raise money?
Persephone Biosciences's most recent round on record is a Seed, in Jul 2022.
What does Persephone Biosciences do?
Persephone Biosciences is a biotechnology company.
Where is Persephone Biosciences headquartered?
Persephone Biosciences is headquartered in San Diego, US.
Which VCs invest in companies like Persephone Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Persephone Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Persephone Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.